Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping the plasma proteomic architecture of systemic lupus erythematosus.

JCI insight·2026
Same author

Sabbatical.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Complement biomarkers during iptacopan treatment.

Lancet (London, England)·2026
Same author

C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A novel fusion protein reduces kidney complement in experimental C3 glomerulopathy.

Clinical and experimental immunology·2026
Same author

Single-Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
Same journal

Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

The Journal of clinical investigation·2026
Same journal

Molecular mechanisms regulating cGAS/STING activation in health and disease.

The Journal of clinical investigation·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

Complement factor H-deficient mice develop spontaneous hepatic tumors.

Jennifer Laskowski1, Brandon Renner1, Matthew C Pickering2

  • 1Department of Medicine, Nephrology and Hypertension, University of Colorado School of Medicine, Aurora, Colorado, USA.

The Journal of Clinical Investigation
|May 6, 2020
PubMed
Summary
This summary is machine-generated.

Complement factor H (CFH) deficiency promotes liver inflammation and hepatocellular carcinoma (HCC) in mice. Loss of CFH function in humans correlates with worse HCC survival, highlighting CFH's protective role.

Keywords:
ComplementImmunologyLiver cancerOncology

More Related Videos

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.7K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

36.9K

Related Experiment Videos

Last Updated: Dec 22, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.7K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

36.9K

Area of Science:

  • Immunology
  • Oncology
  • Hepatology

Background:

  • Hepatocellular carcinoma (HCC) incidence is rising, with poor prognosis.
  • Complement factor H (CFH) regulates the complement alternative pathway (AP) and is linked to inflammatory diseases.
  • The role of CFH in liver inflammation and carcinogenesis is largely unknown.

Purpose of the Study:

  • To investigate the role of CFH in controlling complement activation within the liver.
  • To determine if CFH deficiency contributes to hepatic tumor formation.

Main Methods:

  • Studied aging CFH-deficient (fH-/-) mice and examined their livers for inflammation and tumor formation.
  • Analyzed human HCC biopsies for complement fragment deposition.
  • Correlated CFH mRNA expression and mutations with HCC patient survival using The Cancer Genome Atlas.

Main Results:

  • Spontaneous hepatic tumors developed in over 50% of aged fH-/- male mice.
  • fH-/- livers showed widespread complement fragment deposition, inflammation (elevated transaminases, immune cell infiltration), steatosis, and fibrosis.
  • Human HCC tumors exhibited extensive complement fragment deposition.
  • Increased CFH mRNA correlated with better HCC survival, while mutations correlated with worse survival.

Conclusions:

  • CFH is crucial for suppressing complement activation in the liver.
  • CFH deficiency leads to chronic liver inflammation and promotes hepatocellular carcinoma development.
  • CFH status is a potential prognostic marker for HCC.